SERPINB3 and treatment resistance in cervical cancer
The role of SERPINB3 in cervical cancer therapeutic resistance
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11307156
Trying to make cervical cancers that resist radiation more likely to be killed by targeting a protein called SERPINB3.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11307156 on ClinicalTrials.gov |
What this research studies
Researchers aim to understand why some cervical cancers resist radiation by focusing on a protein called SERPINB3. They work with tumor cells, gene editing (CRISPR), and siRNA in lab and animal tumor models to see whether removing or blocking SERPINB3 makes tumors die when treated with radiation. The team is following a form of cell death called lysoptosis, which happens when lysosomes break open, and looking for molecular signs that predict which tumors are vulnerable. These findings would guide future tests in people and help develop treatments to increase radiation effectiveness.
Who could benefit from this research
Good fit: People with cervical cancer whose tumors show high SERPINB3 levels and who are receiving or eligible for radiation therapy would be the ideal candidates for related future trials.
Not a fit: Patients whose tumors lack high SERPINB3 expression, those not receiving radiation, or those seeking immediate clinical benefit are unlikely to gain direct benefit from this preclinical research.
Why it matters
Potential benefit: If successful, this work could lead to therapies that make radiation more effective for patients with SERPINB3-high cervical tumors, improving tumor control and reducing recurrences.
How similar studies have performed: Early lab and animal experiments showed that removing SERPINB3 can sensitize tumors to radiation, but this approach has not yet been tested or proven in human patients.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MARKOVINA, STEPHANIE — WASHINGTON UNIVERSITY
- Study coordinator: MARKOVINA, STEPHANIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.